List of Excipients in Branded Drug IBRANCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	AMMONIA	2034-08-08
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	CELLULOSE, MICROCRYSTALLINE	2034-08-08
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	DIMETHICONE	2034-08-08
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	FERRIC OXIDE RED	2034-08-08
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	FERRIC OXIDE YELLOW	2034-08-08
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	GELATIN	2034-08-08
Pfizer Laboratories Div Pfizer Inc	IBRANCE	palbociclib	0069-0187	LACTOSE MONOHYDRATE	2034-08-08

Ibrance Excipient Strategy and Commercial Opportunities for Palbociclib

Last updated: August 16, 2026

Ibrance (palbociclib) is a small-molecule CDK4/6 inhibitor marketed by Pfizer for HR-positive, HER2-negative advanced or metastatic breast cancer. Its commercial opportunity has shifted from originator growth to generic manufacturing, excipient optimization, global supply, and lifecycle formulations. The highest-value excipient strategy is a robust immediate-release tablet platform that controls dissolution, limits variability from food and gastric pH, and supports efficient bioequivalence development.

What is Ibrance and how is it formulated?

Ibrance contains palbociclib, a weakly basic, poorly water-soluble active pharmaceutical ingredient. The product is available in 75 mg, 100 mg, and 125 mg strengths as capsules and film-coated tablets. Pfizer introduced the tablet formulation to reduce the clinically relevant food effect associated with the original capsule formulation.

Product attribute	Ibrance profile
Active ingredient	Palbociclib
Therapeutic class	Cyclin-dependent kinase 4/6 inhibitor
Main indication	HR-positive, HER2-negative advanced or metastatic breast cancer
Common combinations	Aromatase inhibitor or fulvestrant; with an LHRH agonist in pre- or perimenopausal patients
Strengths	75 mg, 100 mg, 125 mg
Dosage forms	Capsules and film-coated tablets
Standard schedule	125 mg once daily for 21 consecutive days followed by 7 days off
FDA approval	2015 accelerated approval; regular approval in 2017
Manufacturer	Pfizer
Generic classification	Small-molecule generic, not a biosimilar
Key formulation issue	Palbociclib solubility, dissolution, food effect, and exposure variability

The capsule label identifies lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, and magnesium stearate as core excipients. The capsule shell contains gelatin, titanium dioxide, and colorants. The tablet formulation uses a different excipient system centered on microcrystalline cellulose, colloidal silicon dioxide, crospovidone, and magnesium stearate, with a film coating containing hypromellose, titanium dioxide, triacetin, and colorants. Exact inactive-ingredient details should be controlled against the applicable FDA labeling version before commercialization.[1]

What excipients are used in Ibrance capsules and tablets?

The Ibrance formulation uses conventional immediate-release excipients rather than a high-cost lipid, polymeric, or amorphous solid-dispersion platform. The commercial value lies in process control and dissolution performance.

Excipient or excipient class	Function in palbociclib formulation	Commercial relevance
Lactose monohydrate	Diluent and bulking agent in capsules	Low cost, broad availability, but creates a lactose-free differentiation opportunity
Microcrystalline cellulose	Diluent, compressibility aid, and dry-binder	Critical for tablet robustness and direct-compression processing
Colloidal silicon dioxide	Glidant and flow aid	Supports powder-flow consistency; excessive use can affect compression and dissolution
Sodium starch glycolate	Superdisintegrant in capsules	Promotes capsule-content breakup and drug release
Crospovidone	Superdisintegrant in tablets	Supports rapid tablet disintegration without swelling-related gel formation
Magnesium stearate	Lubricant	Necessary for manufacturability but can slow wetting and dissolution if over-lubricated
Hypromellose	Film-forming coating polymer	Supports appearance, handling, and dose identification
Triacetin	Plasticizer	Improves coating flexibility and reduces cracking
Titanium dioxide and iron oxides	Opacifier and colorants	Supports strength differentiation and product identification
Gelatin	Capsule shell	Standard hard-capsule shell material

What is the key technical problem for excipient selection?

Palbociclib has pH-dependent solubility. As a weak base, it generally dissolves more readily in acidic conditions and less readily as pH rises. Excipients that alter wetting, disintegration, microenvironmental pH, or hydrophobicity can materially affect dissolution and exposure.

The highest-risk excipient variables are:

1. Magnesium stearate concentration and blending time.
2. Disintegrant type and level.
3. Microcrystalline cellulose grade and moisture content.
4. Particle-size distribution of palbociclib.
5. Granulation versus direct compression.
6. Film-coating weight gain.
7. Packaging moisture protection.
8. Residual moisture and tablet hardness.

A generic developer should treat the formulation as a quality-by-design problem rather than as a simple substitution exercise. Excipient changes that appear minor can shift dissolution across pH conditions, particularly where the active has limited intrinsic solubility.

How should a generic manufacturer design an Ibrance excipient platform?

A practical generic platform should use a conventional immediate-release tablet with excipients that are widely available, pharmacopeial, and supported by existing regulatory precedent.

Recommended formulation architecture

The lowest-complexity strategy is:

• Microcrystalline cellulose as the primary diluent.
• Crospovidone or sodium starch glycolate as the principal disintegrant.
• Colloidal silicon dioxide as a flow aid.
• Magnesium stearate at the lowest level that provides acceptable ejection force.
• Hypromellose-based film coating.
• Iron oxide and titanium dioxide for strength differentiation.

A formulation developer should compare direct compression with dry granulation. Direct compression offers lower manufacturing cost and fewer unit operations, but it requires consistent powder flow and compressibility. Dry granulation can improve content uniformity and handling where palbociclib has poor flow or segregation risk.

Wet granulation may improve uniformity but introduces additional moisture and thermal exposure. It is less attractive unless development data show a clear dissolution or manufacturability benefit.

Should a generic use lactose?

Lactose is a commercially efficient diluent, but a lactose-free formulation offers a modest differentiation opportunity. A lactose-free product could use:

• Microcrystalline cellulose.
• Mannitol.
• Dibasic calcium phosphate, if compatibility and dissolution are acceptable.
• Spray-dried lactose alternatives only where the product strategy permits lactose labeling.

The commercial benefit is limited because most patients do not require lactose-free palbociclib. The stronger argument is supply-chain simplification and avoidance of a dairy-derived excipient rather than a major clinical advantage.

Which excipient attributes require tight control?

Critical material attribute	Why it matters
Palbociclib particle size	Affects dissolution and content uniformity
Microcrystalline cellulose grade	Affects tablet hardness, porosity, and disintegration
Disintegrant particle size	Affects breakup time and dissolution
Magnesium stearate specific surface area	Affects lubrication and hydrophobicity
Excipient moisture	Affects compression, stability, and polymorphic behavior
Silica surface area	Affects flow and blend uniformity
Coating permeability	Affects moisture uptake and product stability

The most defensible development package would connect these attributes to comparative dissolution profiles in acidic and near-neutral media, tablet disintegration, assay, content uniformity, degradation products, and stability.

What formulation patents protect Ibrance?

Ibrance is protected by a portfolio covering palbociclib composition, pharmaceutical compositions, therapeutic use, and potentially manufacturing-related subject matter. The relevant commercial question is not whether an individual excipient is patentable. It is whether a proposed generic formulation practices an enforceable claim covering the active, dosage form, method of treatment, or manufacturing process.

Excipient substitution generally does not avoid:

• Composition-of-matter claims covering palbociclib.
• Pharmaceutical-composition claims that are broad enough to cover conventional excipients.
• Method-of-use claims for treating HR-positive, HER2-negative breast cancer.
• Process claims covering selected forms or manufacturing steps.

The FDA Orange Book identifies patents and regulatory exclusivities associated with approved Ibrance products. Patent scope, expiration, pediatric extensions, and litigation outcomes must be assessed against the current Orange Book listing and the relevant U.S. Patent and Trademark Office records.[2]

When does Ibrance lose exclusivity?

Ibrance no longer has new-drug exclusivity blocking ordinary generic development. The commercial barrier is patent enforcement and settlement timing rather than remaining FDA new-drug exclusivity.

Publicly reported patent settlements involving Pfizer and generic manufacturers have generally established delayed-entry arrangements, with widely reported U.S. generic entry timing centered on late 2027 for certain parties. The precise date can differ by defendant, patent, settlement, and regulatory status. A generic developer therefore needs a claim-by-claim freedom-to-operate analysis rather than reliance on a single headline expiration date.

What is the Orange Book status of Ibrance?

Ibrance is an FDA-approved small-molecule product listed in the Orange Book. Approved generic versions use an Abbreviated New Drug Application and must demonstrate pharmaceutical equivalence and bioequivalence, subject to the applicable reference-listed drug and labeling requirements.[2,3]

The Orange Book analysis should cover:

• Reference-listed drug designation.
• Listed patents and expiration dates.
• Use codes for method-of-use patents.
• Pediatric exclusivity.
• Approved strengths and dosage forms.
• Whether a tablet or capsule is being used as the reference product.
• Any therapeutic-equivalence code assigned to approved generics.

A formulation developer should avoid assuming that capsule and tablet development are interchangeable. The dosage form, labeling, food instructions, dissolution requirements, and reference product can affect the ANDA strategy.

Which companies are challenging Ibrance patents?

Ibrance has attracted generic interest because of its large revenue base and relatively conventional oral dosage forms. Public patent litigation and settlement activity has involved multiple generic manufacturers, including large multinational and Indian pharmaceutical companies. The principal market participants have included firms such as Teva, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and other ANDA applicants, depending on the specific patent dispute.

Paragraph IV challenges can create commercial access before the final patent expiry if:

• The challenged patent is invalidated.
• The patent is found not infringed.
• The brand settles for an agreed launch date.
• The relevant patent expires without an effective injunction.

The commercial value of a first-to-file or early-settling position can be substantial. It depends on the number of authorized entrants, the structure of any 180-day exclusivity, the settlement date, and the degree of price erosion after launch.

What generic entry risks exist for Ibrance?

The main risks are legal timing, bioequivalence failure, product liability, and manufacturing scale-up.

Risk	Effect on commercial launch
Patent settlement restriction	Can defer launch despite completed development
Dissolution mismatch	May trigger additional formulation work or regulatory deficiency
Food-effect differences	Can complicate product labeling and bioequivalence
Content-uniformity failure	Increases batch rejection and review risk
Limited API supply	Raises cost and delays launch
Multiple generic entrants	Reduces price and market share rapidly
Oncology adherence concerns	Increases scrutiny of packaging and dose management
Manufacturing transfer	Can change hardness, disintegration, or impurity profile

Because palbociclib is used chronically in oncology, consistent exposure and predictable administration are commercially important. A generic product that produces reliable dissolution across manufacturing sites can have a supply and contracting advantage even if it has no therapeutic differentiation.

What commercial opportunities exist in Ibrance excipients?

1. High-volume excipient supply

The largest near-term opportunity is supplying standard excipients to generic palbociclib manufacturers. The relevant materials are widely used, so price and continuity of supply will dominate unless a supplier offers strong technical documentation or a differentiated grade.

Potential supplier advantages include:

• Low-peroxide and low-moisture grades.
• Consistent particle-size distribution.
• Validated compendial documentation.
• Multiple manufacturing sites.
• Regulatory support for global submissions.
• Excipient change-control packages.
• Small-scale development quantities for bioequivalence batches.

2. Co-processed excipients

A co-processed microcrystalline cellulose and silica system could improve flow, reduce segregation, and support direct compression. A co-processed excipient is more commercially defensible than a commodity-grade excipient if it delivers measurable improvements in:

• Blend uniformity.
• Tablet tensile strength.
• Disintegration.
• Lubricant sensitivity.
• Scale-up reproducibility.

The product must still demonstrate that it does not produce an unanticipated dissolution profile relative to the reference product.

3. Lactose-free and low-allergen products

Lactose-free palbociclib can support hospital procurement, specialty-pharmacy positioning, and global markets with specific excipient preferences. The opportunity is incremental rather than transformational because lactose intolerance does not generally prevent use of pharmaceutical lactose at the quantities present in a tablet or capsule.

4. Moisture-protective packaging

Palbociclib manufacturers may create value through packaging rather than novel excipients. Opportunities include:

• High-barrier blister systems.
• Desiccant-based bottles.
• Unit-dose oncology packaging.
• Child-resistant, adherence-oriented packs.
• Packaging compatible with temperature-sensitive distribution lanes.

Packaging can reduce stability risk when the formulation is sensitive to moisture or when global distribution involves variable humidity.

5. Modified adherence packaging

The 21-days-on, 7-days-off regimen creates a clear packaging opportunity. Calendarized blister packs can reduce dosing errors and support specialty-pharmacy dispensing. Packaging must not imply a new dosing regimen, but it can improve administration clarity.

A commercially attractive system could identify:

• Treatment days.
• The seven-day break.
• Strength and dose.
• Refill timing.
• Concomitant endocrine therapy.

6. Alternative oral dosage forms

Orally disintegrating tablets, mini-tablets, sprinkle capsules, and liquid suspensions could address swallowing difficulty and treatment populations with administration challenges. These products face higher regulatory and clinical risk because they may alter absorption, palatability, dose uniformity, and food instructions.

The strongest near-term opportunity is an improved conventional tablet, not an aggressive reformulation. Alternative dosage forms may require additional clinical bridging and could encounter method-of-use or formulation patent issues.

How does Ibrance compare with competing CDK4/6 inhibitors?

Ibrance competes with Kisqali (ribociclib) and Verzenio (abemaciclib). The products have different dosing schedules, safety profiles, excipient systems, and commercial positioning.

Product	Active ingredient	Dosage form	Typical schedule	Excipient opportunity
Ibrance	Palbociclib	Capsule and tablet	21 days on, 7 days off	Generic tablet, adherence packaging, lactose-free platform
Kisqali	Ribociclib	Tablet	21 days on, 7 days off in many regimens	Immediate-release robustness and global supply
Verzenio	Abemaciclib	Tablet	Continuous dosing in common regimens	High-value adherence and tolerability support

Palbociclib has a comparatively attractive generic formulation opportunity because the product is an oral immediate-release dosage form with well-established excipient classes. Its commercial disadvantage is the likely presence of multiple generic entrants after the permitted launch window.

What is the revenue exposure from Ibrance generic entry?

Pfizer reported approximately $4.8 billion in Ibrance revenue in 2023.[4] That level of sales creates substantial exposure to post-entry price erosion. The impact will depend on:

• The number of generic entrants.
• Entry timing.
• Payer substitution rules.
• Specialty-pharmacy contracting.
• Authorized generic participation.
• International patent status.
• Physician and patient switching behavior.

A conventional generic manufacturer can target manufacturing efficiency and rapid scale. An excipient supplier can target multi-source qualification and global regulatory support. A specialty-packaging provider can target adherence and distribution contracts rather than compete directly on tablet price.

What manufacturing and IP barriers affect commercial launch?

The main manufacturing barrier is not complex technology. It is reproducibility. A successful product must maintain acceptable dissolution, assay, impurities, content uniformity, and stability across commercial-scale batches.

The main IP barrier is claim coverage around palbociclib and its approved uses. Excipient changes can reduce formulation risk but do not eliminate active-ingredient or method-of-use patent exposure.

Geographic coverage also matters. U.S. entry timing may differ from Europe, Japan, Canada, emerging markets, and other jurisdictions. A company can often obtain value by sequencing launches according to local patent expiry, regulatory review, and procurement dynamics.

Key Takeaways

• Ibrance contains palbociclib and is available as 75 mg, 100 mg, and 125 mg capsules and tablets.
• Its core formulation uses conventional excipients, including microcrystalline cellulose, colloidal silicon dioxide, disintegrants, magnesium stearate, and film-coating materials.
• The primary technical challenge is controlling dissolution and exposure for a weakly basic, poorly soluble active.
• A direct-compression or dry-granulated tablet is the most practical generic platform.
• Excipient suppliers can compete through low-moisture grades, co-processed systems, regulatory support, and supply continuity.
• Lactose-free formulations offer modest differentiation, while adherence packaging provides a stronger commercial opportunity.
• Ibrance is a small-molecule generic opportunity, not a biosimilar opportunity.
• Patent settlements and Orange Book listings remain more important to U.S. entry timing than FDA new-drug exclusivity.
• Pfizer reported approximately $4.8 billion in Ibrance revenue in 2023, creating substantial generic-entry exposure.
• The strongest near-term commercial strategy is a robust, low-cost immediate-release tablet supported by reliable excipient sourcing and calendarized packaging.

FAQs

Can a generic Ibrance tablet use different excipients from the reference product?

Yes. An ANDA product can use different inactive ingredients if the formulation meets applicable safety, quality, pharmaceutical-equivalence, labeling, and bioequivalence requirements.

Is palbociclib suitable for an orally disintegrating tablet?

It may be technically feasible, but the product would require careful control of dose uniformity, disintegration, palatability, dissolution, stability, and absorption. It would carry greater development risk than a conventional tablet.

Does Ibrance require a pH-modifying excipient?

Not necessarily. A pH modifier could improve dissolution, but it can also change stability, local gastrointestinal conditions, and exposure. Any acidifier or alkalizer would require comparative dissolution and bioequivalence justification.

Can excipients extend palbociclib market exclusivity?

Usually not by themselves. An excipient change may support a patentable formulation only if it produces a novel, non-obvious, and claimable technical result. It does not automatically extend composition-of-matter or method-of-use protection.

Is an authorized generic likely to affect palbociclib pricing?

Yes. An authorized generic can increase price pressure, influence payer substitution, and reduce the commercial advantage available to independent generic entrants. Its effect depends on launch timing, contracting, and the number of competing ANDA products.

References

1. U.S. Food and Drug Administration. (2024). Ibrance (palbociclib) prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2020). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. https://www.fda.gov/

4. Pfizer Inc. (2024). 2023 annual report. https://www.pfizer.com/investors/financial-reports-annual-reports.